FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
OIAILMENI	OI OIIANGEO	III DEIIEI IOIAE	OWNER

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response	e: 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Palleiko Benjamin L					2. Issuer Name and Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [KALV]									tionship of Reportin all applicable) Director		10% Ow		ner	
(Last)	,	rst) (M	Middle)	,	3. Date of Earliest Transaction (Month/Day/Year) 02/14/2024								X	Office	ficer (give title elow)		Other (specify below)		
	CAMBRIDGE PARKWAY, SUITE 901E					4. If Amendment, Date of Original Filed (Month/Day/Year)							. Individual or Joint/Group Filing (Check Applicabline) X Form filed by One Reporting Person						
(Street) CAMBR	IDGE M	A 0	2142										X	Form filed by More than One Reporting Person					
(City)	(Si	tate) (Ž	Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								nded to						
		Table	I - N	on-Deriva	tive S	Secui	rities	Acc	quire	d, Dis	sposed of	, or B	enefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/			Year)	Execution Date		·	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			d 5)	Securities Beneficially Owned Following		Form (D) or	r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	mon Stock 02/14/2			02/14/20)24	24 s ⁽¹⁾ 40,855 D \$1			\$15.0	5.0093 159,088 D									
		Tal	ble II	- Derivati (e.g., pu							osed of, convertib)wne	t			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exec if any	eemed ution Date, , th/Day/Year)		ransaction ode (Instr.) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			vative (urity (r. 5) I	9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	y G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code			Date Exercisable		Expiration Date	Amour or Numbe of Title Shares								

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

/s/ Benjamin L. Palleiko

02/16/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.